Hospira, a provider of injectable drugs and infusion technologies, has announced the launch of the Sapphire infusion system in the US following regulatory approval from the US Food and Drug Administration (FDA).
The Sapphire features an intuitive color touch-screen, easily upgraded software, and flexible infusion modes.
The Sapphire platform, which is already in use in Europe and Canada, can be used in both home care and acute care settings.
Hospira Medication Management Systems vice president Rich Nevin noted launching the Sapphire infusion pump to the company's US customers demonstrates its commitment to improving medication delivery and strengthens the breadth of our medication management business.
"The Sapphire system was developed to easily adapt to changing clinical needs and allows Hospira to provide clinicians with the most up-to-date device technology," Nevin added.
Q Core Medical CEO Dr Boaz Eitan noted the company is proud to make this important step forward together with Hospira and launch its Sapphire system in the US market.
"This is yet another successful stage in the international cooperation between the companies, and we believe that the combination of our technology with Hospira's excellent customer support and in-depth experience in the U.S. market will begin a new era in infusion solutions for our customers," Dr Eitan added.
Hospira's Sapphire system will be available as a replacement for its retired GemStar ambulatory pumps.
